A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
Status:
Recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant
radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent
radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration
of pembrolizumab will be one year in the experimental arm.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration